Key result
CCM improves symptoms, functional status, and QoL in HF patients by increasing contractility.
Why the study?
Does cardiac contractility modulation improve symptoms and functional status in heart failure patients with LVEF 25-45% who are not candidates for cardiac resynchronization therapy?
Does cardiac contractility modulation improve symptoms and functional status in heart failure patients with LVEF 25-45% who are not candidates for cardiac resynchronization therapy?
Answers are grounded in this paper and cite their sources.
Cardiac contractility modulation is an FDA-approved device therapy that improves symptoms and quality of life in heart failure patients with LVEF 25-45% who are ineligible for CRT.
Cardiac contractility modulation (CCM) is a novel therapeutic approach for heart failure patients, which utilizes nonexcitatory electrical myocardial stimulation in the absolute refractory period of the cardiac cycle. This stimulation has been shown to increase contractility, leading to improved heart failure symptoms, functional status, and quality of life. CCM is FDA approved for heart failure patients with an LVEF between 25% and 45% who remained symptomatic despite optimal medical therapy and not candidate of cardiac resynchronization therapy. CCM offers expanded treatment options for heart failure patients who have continued symptoms while on optimal medical therapy.
No takes yet. Share an insight, caveat, or question.
Wallner et al. (2026) conducted a review in Heart failure. Cardiac contractility modulation (CCM) was evaluated. Cardiac contractility modulation is a novel therapeutic approach that increases contractility and improves symptoms, functional status, and quality of life in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: